. "P\u0159edm\u011Btem projektu je v\u00FDvoj origin\u00E1ln\u00EDho antiastmatika V\u00DAFB-19 363. V jeho r\u00E1mci bude provedeno preklinick\u00E9 hodnocen\u00ED a klinick\u00E9 zkou\u0161en\u00ED do ukon\u010Den\u00ED pilotn\u00ED studie II. f\u00E1ze. Sou\u010D\u00E1st\u00ED \u0159e\u0161en\u00ED je i vypracov\u00E1n\u00ED nab\u00EDdkov\u00E9 dokumentace, jej\u00EDm\u017E \u00FA\u010Delem je vyhled\u00E1n\u00ED vhodn\u00E9ho strategick\u00E9ho partnera pro spolufinancov\u00E1n\u00ED dokon\u010Den\u00ED klinick\u00E9ho zkou\u0161en\u00ED. Bude pokra\u010Dovat vyhled\u00E1vac\u00ED v\u00FDzkum, aby byla udr\u017Eov\u00E1na kontinuita se sv\u011Btov\u00FDmi trendy v terapeutick\u00FDch kategori\u00EDch protiz\u00E1n\u011Btliv\u00FDch l\u00E9\u010Div." . . . "Preklinick\u00E9 hodnocen\u00ED l\u00E1tky V\u00DAFB 19363 jako potencion\u00E1l. antiastmatika s antileukotrienov\u00FDm mechanismem \u00FA\u010Dinku. Provedeny toxikolog. a farmakokinet. studie na zv\u00ED\u0159atech, \u0161irok\u00E9 srovn\u00E1vac\u00ED biologick\u00E9 hodnocen\u00ED aktivn\u00ED l\u00E1tky. L\u00E1tka patentov\u00E1na."@cs . . "1"^^ . . " preclinical evaluation" . "1"^^ . "original antiastmatic" . . "2"^^ . "The development of VUFB-19 363, the original antiastmatic with multiple mechanism of action."@en . . "2"^^ . "FB-C3/09" . . . "0"^^ . . "2002-12-19+01:00"^^ . . . "V\u00FDvoj origin\u00E1ln\u00EDho antiastmatika V\u00DAFB-19 363 s v\u00EDce\u010Detn\u00FDm mechanismem \u00FA\u010Dinku." . . "original antiastmatic; preclinical evaluation; offering documentation"@en . . "http://www.isvav.cz/projectDetail.do?rowId=FB-C3/09"^^ . . . "The project is dealing with the development of original antiastmatic V\u00DAFB-19 363. The preclinical evaluation and clinical testing including the pilot study of the 2nd phase will be performed. The offering documentation as the additional result will be elaborated during the project. This documentation will be used for the discovery of suitable strategic partner for the financial support of further clinical evaluation. The research of antiinflammatory compounds will be continued during the mentioned period."@en . .